- Home
- MERC vs ESLA Comparison
MERC vs ESLA Comparison
Compare MERC & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MERC | ESLA |
|---|---|---|
| Founded | 1968 | 2021 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.0M | 69.5M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | MERC | ESLA |
|---|---|---|
| Price | $1.00 | $1.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.25 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 589.6K | 28.7K |
| Earning Date | 05-07-2026 | 05-26-2026 |
| Dividend Yield | ★ 7.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,169,145,000.00 | N/A |
| Revenue This Year | $13.75 | N/A |
| Revenue Next Year | $10.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $0.75 | $0.78 |
| 52 Week High | $4.47 | $3.15 |
Technical Indicators
Market Signals| Indicator | MERC | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 36.98 |
| Support Level | $0.75 | $0.97 |
| Resistance Level | $1.20 | $1.35 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 63.75 | 15.62 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.